Drug Research
Drug Discovery & Development

4-Antibody - Therapeutic Antibody Technology

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform, which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in-vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates.

In-vitro Retrocyte Display® technology

Retrocyte Display generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells (the cell designed by nature for optimal antibody display).

Image 1

4-Antibody provides access to its technologies to pharmaceutical R&D collaborators but is also generating its own pipeline of antibody drugs. The Company's lead development product is an anti-cytomegalovirus antibody drug.

4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland and Jena, Germany.

Reduce development risk as early as possible in the antibody discovery process

With many different antibody discovery technologies now available to corporate pharma, 4-Antibody has differentiated its technology offering by utilizing a B-cell display approach which combines the fidelity of mammalian B cell expression with the efficiency of an in vitro high throughput display process to rapidly discover molecules with favorable performance characteristics as development leads.

Image 2

4-Antibody aims to reduce development risk as early as possible in the antibody discovery process by selecting molecules more likely to display 'better behavior' as drug candidates.

Working with Ludwig Institute for Cancer Research & the Memorial Sloan Kettering Cancer Centre

Retrocyte Display is a high-throughput in vitro discovery process utilizing cellular expression libraries encoding full length human antibodies in B-lineage cells, thus mimicking nature's own antibody generation process. This approach has been designed to reject molecules with less desirable drug characteristics as early as possible in the discovery process, and to deliver lead molecules for preclinical characterization which can be viewed as 'development ready' early in discovery with a resulting enhanced likelihood of eventual biological and physiological success.

image 3

In addition to partnering its technology platform with corporate pharma, 4-Antibody is now applying its Retrocyte Display technology in an R&D collaboration with the Ludwig Institute for Cancer Research & the Memorial Sloan Kettering Cancer Center in New York to develop therapeutic antibodies directed to a series of molecular targets with key roles in the suppression of immune responses in cancer patients


4-Antibody AG
Hochbergerstrasse 60C
CH-4057 Basel
Tel: +41 61 633 22 60
Fax: +41 61 633 22 61

Affiliate Germany
Winzerlaer Strasse 2
D-07745 Jena
Tel: +49 (0)3641 508 230
Fax: +49 (0)3641 508 113
Email: info@4-antibody.com
URL: www.4-antibody.com